Stock futures rally as Nvidia’s strong forecast reignites the AI trade: Live updates

Stock futures rally as Nvidia’s strong forecast reignites the AI trade: Live updates


Traders work at the New York Stock Exchange on Nov. 19, 2025.

NYSE

Stock futures rose Thursday as investors digested Nvidia’s latest quarterly beat. The report appeared to help restore confidence in major technology stocks, providing a boost to the broader market.

Futures tied to the Dow Jones Industrial Average added 235 points, or 0.5%. S&P 500 futures rose 1.1%, while Nasdaq 100 futures jumped 1.6%.

Nvidia shares jumped nearly 5% in premarket trading after the chipmaker released its highly anticipated quarterly results, which beat Wall Street’s earnings and revenue expectations. The market-moving company also gave a stronger-than-expected fourth-quarter sales forecast, with CEO Jensen Huang saying demand for its current-generation Blackwell chips are “off the charts.” He also rejected the idea of an AI bubble.

Nvidia’s upbeat guidance likely lifted investor sentiment around the AI trade, which has weakened in recent sessions amid fears about elevated valuations, debt financing and potential chip depreciation. The results boosted a slew of stocks across the AI ecosystem in the after-hours session, including chipmakers Advanced Micro Devices and Broadcom and power infrastructure companies such as Eaton.

“Nvidia’s numbers remain extremely strong now, but there are inevitably questions whether Huang’s company has already reached its high-water mark in terms of growth and market share,” said David Russell, TradeStation’s global head of market strategy. 

In the previous session, all three major U.S. stock indexes rose across the board as investors awaited Nvidia’s report. Gains in the S&P 500 and Dow Jones Industrial Average snapped a four-day slide for both indexes. To be sure, stocks are in the red for the week given the depth of the recent pullback in several growth stocks.

Minutes from the Federal Reserve’s October meeting released Wednesday afternoon showed disagreements between Fed officials over whether a slowing labor market or inflation were bigger threats to the U.S. economy. The divide between central bank officials is also reflected in their outlook for their upcoming December decision, with “many” officials calling for no more interest rate cuts this year. Traders are pricing in a 33% likelihood that the Fed will cut its benchmark overnight borrowing rate by a quarter percentage point during its upcoming December meeting, significantly lower than their bets just a month ago, per the CME FedWatch Tool.

On Thursday morning, the Bureau of Labor Statistics will release September nonfarm payrolls data, which was delayed by the U.S. government shutdown.



Source

Trump says India will buy oil from Venezuela
World

Trump says India will buy oil from Venezuela

U.S. President Donald Trump on Saturday said India will buy Venezuelan oil, helping to replace some of the Russian oil that the world’s third-biggest oil importer buys. “We’ve already made that deal, the concept of the deal,” Trump told reporters aboard Air Force One as he traveled to his vacation home in Florida from Washington. […]

Read More
India’s finance minister projects modest fiscal consolidation in budget
World

India’s finance minister projects modest fiscal consolidation in budget

India’s government plans a modest improvement in its fiscal picture in the coming financial year, with reductions in the fiscal deficit and debt, while boosting manufacturing in sectors ranging from textiles to chips. Finance Minister Nirmala Sitharaman, in her ninth consecutive budget speech, said on Sunday that the government sees its fiscal deficit falling to […]

Read More
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation
World

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China’s tempting innovation

Pharma giant AstraZeneca will list on the New York Stock Exchange on Monday, days after it announced big commitments on the other side of the world. Like the rest of Big Pharma, the company has a balancing act. It wants a close relationship with the U.S., its biggest market, and the listing is intended to […]

Read More